NCT03026140 2026-03-05
NICHE
The Netherlands Cancer Institute
Phase 2 Recruiting
Clinical Trials
100 trialsNCT05731726 2026-03-05
Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
Zhejiang University
Phase 2 Recruiting
NCT02574728 2026-03-02
AflacST1502
Emory University
Phase 2 Active not recruiting
NCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
NCT01356290 2026-02-23
MEMMAT
Medical University of Vienna
Phase 2 Recruiting
NCT03926338 2025-11-20
PICC
Sun Yat-sen University
Phase 2 Recruiting
NCT07154316 2025-09-04
Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer
Fudan University
Phase 2 Recruiting
NCT07150949 2025-09-02
Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)
Fudan University
Phase 2 Recruiting
NCT07104266 2025-08-05
Triple Negative Breast Cancer and Celecoxib. Pilot Study
Université de Sherbrooke
Phase 2 Recruiting
NCT06997068 2025-07-14
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population
Mayo Clinic
Phase 2 Recruiting
NCT06903858 2025-04-01
PICC-3
Sun Yat-sen University
Phase 2 Recruiting
NCT04162873 2025-02-12
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
University of Utah
Phase 2 Terminated
NCT03084536 2024-12-24
PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
Washington University School of Medicine
Phase 2 Completed
NCT02641314 2024-05-10
METRO-NB2012
University of Cologne
Phase 2 Completed
NCT05578287 2023-12-07
DETECT
Sun Yat-sen University
Phase 2 Unknown
NCT00665457 2023-09-13
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
University of Nebraska
Phase 2 Terminated
NCT00846430 2023-08-30
Medical Treatment of "High-Risk" Neurofibromas
Corewell Health West
Phase 2 Completed
NCT00538031 2023-04-21
Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
City of Hope Medical Center
Phase 2 Completed
NCT00503035 2023-02-13
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02748707 2022-04-28
ERLO-XIB
Tata Memorial Hospital
Phase 2 Unknown
NCT03403634 2022-03-02
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
Roswell Park Cancer Institute
Phase 2 Completed
NCT02484664 2022-01-20
COLA
Brigham and Women's Hospital
Phase 2 Completed
NCT00112502 2021-10-18
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00033371 2020-09-29
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Phase 2 Completed
NCT00020878 2020-08-03
Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00062179 2020-08-03
Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT02280694 2020-02-12
LDMchemoCRC
HaEmek Medical Center, Israel
Phase 2 Completed
NCT03896113 2020-01-10
CELEBRIDO
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Unknown
NCT03185871 2019-11-15
Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses
University of Wisconsin, Madison
Phase 2 Withdrawn
NCT03864575 2019-07-12
NICE-COMBO
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Unknown
NCT00022399 2019-02-08
Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00256321 2019-02-08
Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma
University of California, Irvine
Phase 2 Terminated
NCT00068432 2018-10-31
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00080782 2018-10-31
Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00088972 2018-08-10
S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women
SWOG Cancer Research Network
Phase 2 Terminated
NCT01220973 2018-06-08
Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT03498326 2018-05-30
GCRP
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT00052611 2018-03-29
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01729923 2018-01-16
ADAPT
University of Washington
Phase 2 Terminated
NCT01695226 2018-01-09
Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer
Maastricht University Medical Center
Phase 2 Completed
NCT00137852 2017-09-20
Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00047281 2017-07-11
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00047294 2017-07-11
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00582660 2017-06-15
UAB0040
University of Alabama at Birmingham
Phase 2 Completed
NCT02840162 2017-04-28
Pre-Prostatectomy Celecoxib or Placebo
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00520845 2017-03-20
Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00056082 2017-02-15
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
University of Kansas Medical Center
Phase 2 Completed
NCT00045591 2017-01-11
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT00099047 2016-12-30
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00081224 2016-12-15
Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum
Alliance for Clinical Trials in Oncology
Phase 2 Terminated